Bioject Medical Technologies, a developer of needle-free injection therapy systems, will provide its Intradermal (ID) Pen, a disposable-syringe jet injector (DSJI), to World Health Organization (WHO) and PATH, to advance the use of DSJIs in developing countries.
Bioject provides support for efforts to advance clinical research of intradermal delivery of vaccines in developing-country immunization programs to advance the use of DSJIs, reducing risks associated with needle reuse and needlestick injuries.
Bioject’s ID Pen spring-powered needle-free injector, currently under development and not yet cleared by the FDA, is intended to be used for intradermal injections for vaccinations and drug therapy.
The system consists of a hand-held, user-filled device that incorporates single-use, auto-disable disposable syringes.
The ID Pen is designed to deliver 0.05mL or 0.10mL for each injection and is entirely mechanical and is intended for administration by trained health workers.
The ID Pen is intended to improve the safety and ease of ID delivery of vaccines and could enable immunization programs to stretch their vaccine supplies across a larger number of beneficiaries.
Bioject executive vice president and chief medical officer Richard Stout said the collaboration advances the development of a new needle-free ID Pen injector, especially after learning of the exciting study results reported in the New England Journal of Medicine using their established B2000 device to investigate intradermal delivery of polio vaccine.
"This new ID Pen injector will provide the needed technology for delivery of vaccines and drugs using the intradermal approach and perhaps allow a dose sparing effect," Stout said.